Sensor-Derived Glycemic Metrics in Women with Type 1 Diabetes Using Insulin Degludec Versus Other Basal Insulin Analogs During Pregnancy—A Post Hoc Analysis of the CopenFast Trial
In this post hoc analysis, pregnant women with type 1 diabetes using degludec achieved lower nighttime TIRp, experienced less severe hypoglycemia, and delivered infants who were heavier and thereby had less appropriate size compared with women using other basal insulin analogs.
Authors
- Julie Carstens Søholm (ORCID: https://orcid.org/0000-0002-4936-8936)
- Kirsten Nørgaard (ORCID: https://orcid.org/0000-0003-1620-8271)
- Elisabeth R. Mathiesen (ORCID: https://orcid.org/0000-0003-3279-0863)
- Sidse Kjærhus Nørgaard (ORCID: https://orcid.org/0000-0002-6664-5755)
- Lene Ringholm (ORCID: https://orcid.org/0000-0003-2971-8043)
- Peter Damm (ORCID: https://orcid.org/0000-0002-2067-5246)
- Tine D. Clausen (ORCID: https://orcid.org/0000-0001-5585-2153)
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Novo Nordisk (Denmark) (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- Women s Health Reports
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1177/26884844251378015
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Novo Nordisk
- Rigshospitalet